RXRXCAUTIOUS

Gross Margin

-93.0%

Higher than 2% of Healthcare sector peers

Updated 1078h ago

Sector Performance

2th percentile

RXRX

-93.0%

Sector Median

68.9%

Sector Avg

-20.2%

📊

Deep Analysis

Recursion Pharmaceuticals, Inc. (RXRX) has a Gross Margin of -93.0% as of May 2026.

This places RXRX in the 2th percentile of the Healthcare sector, which has a median Gross Margin of 68.9% and a sector average of -20.2%. RXRX's Gross Margin is 235.0% below the sector median, a significant divergence that warrants closer examination. In context: Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.

Frequently Asked Questions

What does the Gross Margin tell investors about RXRX?

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.

How is the Gross Margin calculated?

Gross Margin is calculated as: Gross Profit / Revenue.

How does RXRX's Gross Margin compare to its sector?

RXRX's Gross Margin of -93.0% compares to a Healthcare sector median of 68.9%, placing it in the 2th percentile.

Who are RXRX's closest peers by Gross Margin?

The closest Healthcare peers by Gross Margin include: BLUE (68.4%), AMGN (68.2%), TDOC (67.8%), TECH (66.9%), NTRA (64.8%).

The Formula

Gross Profit / Revenue

Why It Matters

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.